Roche (OTCMKTS:RHHBY) Coverage Initiated at Morgan Stanley

Analysts at Morgan Stanley initiated coverage on shares of Roche (OTCMKTS:RHHBY) in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set an “equal weight” rating on the stock.

Separately, Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Roche has an average rating of “Hold”.

Roche Stock Performance

Shares of RHHBY stock opened at $39.43 on Wednesday. The stock’s fifty day simple moving average is $36.70 and its 200 day simple moving average is $38.31. Roche has a twelve month low of $29.20 and a twelve month high of $42.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Brooklyn Investment Group bought a new stake in shares of Roche during the 3rd quarter valued at about $40,000. AlphaMark Advisors LLC bought a new position in shares of Roche during the 3rd quarter worth approximately $149,000. IHT Wealth Management LLC acquired a new stake in shares of Roche during the 3rd quarter worth approximately $236,000. Verity Asset Management Inc. bought a new stake in shares of Roche in the 3rd quarter valued at $253,000. Finally, Canopy Partners LLC lifted its position in shares of Roche by 4.6% during the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after acquiring an additional 344 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.